Format

Send to

Choose Destination
Mem Inst Oswaldo Cruz. 2016 May 24;111(6):365-71. doi: 10.1590/0074-02760160006.

Serological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern Argentina.

Author information

1
Instituto de Investigaciones en Ingeniería Genética y Biología Molecular, Consejo Nacional de Investigaciones Científicas y Tecnológicas, Buenos Aires , Argentina, Instituto de Investigaciones en Ingeniería Genética y Biología Molecular, Consejo Nacional de Investigaciones Científicas y Tecnológicas, Buenos Aires, Argentina.
2
Hospital de Niños Dr. Ricardo Gutiérrez, Hospital de Niños Ricardo Gutiérrez, Buenos Aires , Argentina, Hospital de Niños Ricardo Gutiérrez, Servicio de Parasitología y Chagas, Buenos Aires, Argentina.
3
Centro Asistencial Cáritas Diocesana, Santiago del Estero , Argentina, Centro Asistencial Cáritas Diocesana, Añatuya, Santiago del Estero, Argentina.
4
Hospital Zonal Añatuya, Santiago del Estero , Argentina, Hospital Zonal Añatuya, Santiago del Estero, Argentina.

Abstract

This study aimed to evaluate well-documented diagnostic antigens, named B13, 1F8 and JL7 recombinant proteins, as potential markers of seroconversion in treated chagasic patients. Prospective study, involving 203 patients treated with benznidazole, was conducted from endemic areas of northern Argentina. Follow-up was possible in 107 out of them and blood samples were taken for serology and PCR assays before and 2, 3, 6, 12, 24 and 36 months after treatment initiation. Reactivity against Trypanosoma cruzi lysate and recombinant antigens was measured by ELISA. The rate of decrease of antibody titers showed nonlinear kinetics with an abrupt drop within the first three months after initiation of treatment for all studied antigens, followed by a plateau displaying a low decay until the end of follow-up. At this point, anti-B13, anti-1F8 and anti-JL7 titers were relatively close to the cut-off line, while anti-T. cruzi antibodies still remained positive. At baseline, 60.8% (45/74) of analysed patients tested positive for parasite DNA by PCR and during the follow-up period in 34 out of 45 positive samples (75.5%) could not be detected T. cruzi DNA. Our results suggest that these antigens might be useful as early markers for monitoring antiparasitic treatment in chronic Chagas disease.

PMID:
27223650
PMCID:
PMC4909034
DOI:
10.1590/0074-02760160006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Scientific Electronic Library Online Icon for PubMed Central
Loading ...
Support Center